What does early access actually mean?

Early access programmes allow patients to access drugs which are not yet fully licenced, but where data suggests they could make a transformative difference to their condition.

Known by many names, including compassionate use, these programmes help to provide vital care to patients while the regulatory process is finalised, and have the potential to provide attentional data and real-world insight into the use of new drugs.

In this webinar, Beacon, Metabolic Support UK and Bionical Emas outline the basic principles of early access programmes, their value to industry and patients, and the role that patient groups can play in ensuring their establishment and success.